Nitric oxide as a signaling molecule in the vascular system: An overview

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 6, 1999, Pages 879-886

  Ignarro, Louis J ^a   Cirino, Giuseppe ^b   Casini, Alessandro ^c,e   Napoli, Claudio ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c A Menarini Pharmaceutical Industries Ltd   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Menarini Ricerche SpA   (Italy)

Author keywords

Atherosclerosis; Cyclic GMP; Endothelium; Hypertension; Nitroglycerin; NO synthase; Platelet aggregation; Vasodilation

Indexed keywords

ACETYLSALICYLIC ACID; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCEROL NITRATE; NEBIVOLOL; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; SILDENAFIL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; ENDOTHELIUM; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESEARCH; SIGNAL TRANSDUCTION; SMOOTH MUSCLE TONE; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; BLOOD VESSELS; HUMANS; NITRIC OXIDE; SIGNAL TRANSDUCTION;

EID: 0032707717     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199912000-00016     Document Type: Article

References (114)

1. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro LJ. Relaxation of bovine coronary artery and activation of coronary arterial guanylale cyclase by nitric oxide, nitroprusside and carcinogenic nitrosoamine. J Cyclic Nucleotide Protein Phosphor Res 1979;5:211-24.
2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
3. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981;57:946-55.
4. Mellion BT, Ignarro LJ, Myers CB, et al. Inhibition of human platelet aggregation by S-nitrosothiols: heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol 1983;23:653-64.
5. Gruetter CA, Barry BK, McNamara DB, Kadowitz PJ, Ignarro LJ. Coronary arterial relaxation and guanylale cyclase activation by cigaretle smoke, N′-nitrosonornicotine and nitric oxide. J Pharmacol Exp Ther 1980;214:9-15.
6. Gruetter DY, Gruetter CA, Barry BK, et al. Activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside, and nitrosoguanidine: inhibition by calcium, lanthanum, and other cations, enhancement by thiols. Biochem Phannacol 1980;29: 2943-50.
7. Gruetter CA, Gruetter DY, Lyon JE, Kadowitz PJ, Ignarro LJ. Relationship between cyclic guanosine 3′,5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrale, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J Phannacol Exp Ther 1981; 219:181-6.
8. Ignarro LJ, Gruetter CA. Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: possible involvemenl of S-nitrosothiols. Biochim Biophys Acta 1980;631:221-31.
9. Ignarro LJ, Edwards JC, Gruetter DY, Barry BK, Gruetter CA. Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. FEBS Lett 1980;110: 275-8.
10. Ignairo LJ, Barry BK, Gruetter DY, et al. Guanylate cyclase activation of nitroprusside and nitrosoguanidine is related to formation of S-nitrosothiol intermediates. Biochem Biophys Res Commun 1980;94:93-100.
11. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981; 218:739-49.
12. Ohlstein EH, Barry BK, Gruetter DY, Ignarro LJ. Methemoglobin blockade of coronary arterial soluble guanylate cyclase activation by nitroso compounds and its reversal with dithiothreitol. FEBS Lett 1979;102:316-20.
13. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977; 3:23-35.
14. Needleman P, Johnson EM. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973;184:709-15.
15. Needleman P, Jakschik B, Johnson EM. Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 1973;187:324-31.
16. Axelsson KL, Anderson RGG, Wikberg JES. Vascular smooth muscle relaxation by nitrocompounds: reduced relaxation and cGMP elevation in tolerant vessels and reversal of tolerance by dithiothreitol. Acta Pharmacol Toxicol 1982;50:350-7.
17. Axelsson KL, Andersson RG. Tolerance toward nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 1983;88:71-9.
18. Horowitz JD, Antman EM, Lorell BH, Barry WH, Smith TW. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983;68:1247-53.
19. Keith RA, Burkman AM, Sokoloski TD, Fertel RH. Vascular tolerance to nitroglycerin and cyclic GMP generation in rat aortic smooth muscle. J Pharmacol Exp Ther 1982;221:525-31.
20. May DC, Popma JJ, Black WH, et al. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 1987;317:805-9.
21. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
22. Winniford MD, Kennedy PL, Wells PJ, Hillis LD. Potentiation of nitroglycerin-induced coronary dilatation by N-acetylcysteine. Circulation 1986;73:138-42.
23. DeRubertis FR, Craven PA. Calcium-independent modulation of cyclic GMP and activation of guanylate cyclase by nitrosamines. Science 1976;193:897-9.
24. Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol 1985;25:171-91.
25. Craven PA, DeRubertis FR, Melhem M. Nitric oxide in diabetic nephropathy. Kidney Int Suppl 1997;60:S46-53.
26. Gerzer R, Hofmann F, Schultz G. Purification of a soluble, sodium-nitroprusside-stimulated guanylate cyclase from bovine lung. Eur J Biochem 1981;116:479-86.
27. Gerzer R, Radany EW, Garbers DL. The separation of the heme and apoheme forms of soluble guanylate cyclase. Biochem Biophys Res Commun 1982;108:678-86.
28. Ignarro LJ, Wood KS, Wolin MS. Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc Natl Acad Sci U S A 1982;79:2870-3.
29. Ignarro LJ, Degnan JN, Baricos WH, Kadowitz PJ, Wolin MS. Activation of purified guanylate cyclase by nitric oxide requires heme: comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta 1982;718:49-59.
30. Ignarro LJ, Wood KS, Ballot B, Wolin MS. Guanylate cyclase from bovine lung: evidence that enzyme activation by phenylhydrazine is mediated by iron-phenyl hemoprotein complexes. J Biol Chem 1984;259:5923-31.
31. Ignarro LJ, Ballot B, Wood KS. Regulation of soluble guanylate cyclase activity by porphyrins and metalloporphyrins. J Biol Chem 1984;259:6201-7.
32. Ohlstein EH, Wood KS, Ignarro LJ. Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. Arch Biochem Biophys 1982;218:187-98.
33. Wolin MS, Wood KS, Ignarro LJ. Guanylate cyclase from bovine lung: a kinetic analysis of the regulation of the purified soluble enzyme by protoporphyrin IX, heme, and nitrosyl-heme. J Biol Chem 1982;257:13312-20.
34. Ignarro LJ, Wood KS, Wolin MS. Regulation of purified soluble guanylate cyclase by porphyrins and metalloporphyrins: a unifying concept. Adv Cyclic Nucleotide Protein Phosphorylation Res 1984;17:267-74.
35. Martin W, Furchgott RF, Villani GM, Jothianandan D. Phosphodiesterase inhibitors induce endothelium dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J Pharmacol Exp Ther 1986;237:539-47.
36. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986;78:1-5.
37. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;3:2007-18.
38. Forstermann U, Pollock JS, Schmidt HH, Heller M, Murad F. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88:1788-92.
39. 2+ sources. Chem Biol 1996; 3:655-9.
40. Gorren AC, Schrammel A, Schmidt K, Mayer B. Decomposition of S-nitrosoglutathione in the presence of copper ions and glutathione. Arch Biochem Biophys 1996;330:219-28.
41. Williams DL. S-nitrosothiols and role of metal ions in decomposition to nitric oxide. Methods Enzymol 1996;268:299-308.
42. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84:9265-9.
43. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987;61:866-79.
44. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
45. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-6.
46. Ignarro LJ, Harbison RG, Wood KS, Kadowitz PJ. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 1986;237:893-900.
47. Ignarro LJ, Wood KS, Byrns RE. Pharmacological and biochemical properties of endothelium-derived relaxing factor (EDRF): evidence that EDRF is closely related to nitric oxide (NO) radical [Abstract]. Circulation 1986;74:II-287.
48. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6.
49. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-7.
50. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990;87:1620-4.
51. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986;88:411-5.
52. Ignarro LJ, Byrns RE, Wood KS. Endothelium-dependent modulation of cGMP levels and intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein. Circ Res 1987;60: 82-92.
53. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989;65:1-21.
54. Ignarro LJ, Gold ME, Buga GM, et al. Basic polyamino acids rich in arginine, lysine, or ornithine cause both enhancement of and refractoriness to formation of endothelium-derived nitric oxide in pulmonary artery and vein. Circ Res 1989;64:315-29.
55. L-Arginine-dependent vascular smooth muscle relaxation and cGMP formation. Am J Physiol 1990;259:H1813-21.
56. G-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun 1989;160: 881-6.
57. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A 1989;86:3375-8.
58. L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release. J Pharmacol Exp Ther 1991;257: 1208-15.
59. Bevan JA, Joyce EH. Flow-dependent dilation in myograph-mounted resistance artery segments. Blood Vessels 1988;25: 101-4.
60. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991;17:187-93.
61. Hintze TH, Vatner SF. Reactive dilation of large coronary arteries in conscious dogs. Circ Res 1984;54:50-7.
62. Holtz J, Giesler M, Bassenge E. Two dilatory mechanisms of antianginal drugs on epicardial coronary arteries in vivo: indirect, flow-dependent, endothelium-mediated dilation and direct smooth muscle relaxation. Z Kardiol 1983;72:98-106.
63. Holtz J, Forstermann U, Pohl U, Giesler M, Bassenge E. Flow-dependent, endothelium-mediated dilation of epicardial coronary arteries in conscious dogs: effects of cyclooxygenase inhibition. J Cardiovasc Pharmacol 1984;6:1161-9.
64. Hull SS, Kaiser L, Jaffe MD, Sparks HV. Endothelium-dependent flow-induced dilation of canine femoral and saphenous arteries. Blood Vessels 1986;23:183-98.
65. Kaiser L, Hull SS Jr, Sparks HV Jr. Methylene blue and ETYA block flow-dependent dilation in canine femoral artery. Am J Physiol 1986;250:H974-81.
66. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250: H1145-9.
67. Tesfamariam B, Halpern W, Osol G. Effects of perfusion and endothelium on the reactivity of isolated resistance arteries. Blood Vessels 1985;22:301-5.
68. Ayajiki K, Kindermann M, Hecker M, Fleming I, Busse R. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ Res 1996;78:750-8.
69. Fleming I, Bauersachs J, Busse R. Calcium-dependent and calcium-independent activation of the endothelial NO synthase. J Vasc Res 1997;34:165-74.
70. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999;31:61-74.
71. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
72. Shimokawa H, Vanhoutte PM. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res 1989;64:900-14.
73. Vanhoutte PM. Hypercholesterolaemia, atherosclerosis and release of endothelium-derived relaxing factor by aggregating platelets. Eur Heart J 1991;12(suppl):E25-32.
74. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991;84:1984-92.
75. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J 1997;18(suppl):E19-29.
76. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
77. Vogel RA, Corretti MC, Gellman J. Cholesterol, cholesterol lowering, and endothelial function. Prog Cardiovasc Dis 1998;41: 117-36.
78. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-6.
79. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-34.
80. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
81. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-5.
82. Napoli C, D'Armiento FP, Mancini FP, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997;100:2680-90.
83. Napoli C, Witztum JL, de Nigris F, Palumbo G, D'Armiento FP, Palinski W. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia induced fatty streak formation than extracranial arteries. Circulation 1999;99:2003-10.
84. Jessup W. Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol 1996;7:274-80.
85. Napoli C, Paternò R, Faraci FM, Taguchi H, Postiglione A, Heistad DD. Mildly oxidized low-density lipoprotein impairs responses of carotid but not basilar artery in rabbits. Stroke 1997; 28:2266-72.
86. Murad F. Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Recent Prog Horm Res 1998;53:43-59.
87. Wever RM, Luscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998;97:108-12.
88. L-arginine. Biochem Biophys Res Commun 1992;189:242-9.
89. Buga GM, Griscavage JM, Rogers NE, Ignarro LJ. Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res 1993;73:808-12.
90. Cohen GA, Hobbs AJ, Fitch RM, Zinner MJ, Chaudhuri G, Ignarro LJ. Nitric oxide regulates endothelium-dependent vasodilator responses in rabbit hindquarters vascular bed in vivo. Am J Physiol 1996;271:H133-9.
91. Abu-Soud HM, Wang J, Rousseau DL, Fukuto JM, Ignarro LJ, Stuehr DJ. Neuronal nitric oxide synthase self-inactivates by forming a ferrous-nitrosyl complex during aerobic catalysis. J Biol Chem 1995;270:22997-3006.
92. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;170:843-50.
93. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-4.
94. Trigo-Rocha F, Aronson WJ, Hohenfellner M, Ignarro LJ, Rajfer J, Lue TF. Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs. Am J Physiol 1993;264:H419-22.
95. L-arginine by constitutive nitric oxide synthase present in rabbit corpus cavernosum. Biochem Biophys Res Commun 1992;186:308-14.
96. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83: 35C-44C.
97. Cleophas TJ. Experimental evidences of selective antagonistic action of nebivolol on α-1-adrenergic receptors. J Clin Med 1998; 2:2-25.
98. Gao Y, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine arteries. J Cardiovasc Pharmacol 1991;17:964-9.
99. Bowman AJ, Chen CPLH, Ford GA. Nitric oxide mediated venodilator effect of nebivolol. Br J Clin Pharmacol 1994;38:199-204.
100. L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71.
101. Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J 1998;19(suppl):J7-15.
102. Dijkhorst-Oei LT, Beutler JJ, Stroes ES, Koomans HA, Rabelink TJ. Divergent effects of ACE inhibition and calcium channel blockers blockade on NO-activity in systemic and renal circulation in essential hypertension. Cardiovasc Res 1998;40:402-9.
103. Schiffrin EL. Vascular protection with newer antihypertensive agents. J Hypertens 1998;61:525-9.
104. Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol 1998;275:F849-62.
105. Wallace JL, McKnight W, Del Soldato P, Baydoun A, Cirino G. Antithrombotic effects of a nitric oxide-releasing, gastric sparing aspirin derivative. J Clin Invest 1995;96:2711-8.
106. Fiorucci S, Antonelli E, Santucci L, et al. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 1999;116:1089-106.
107. Wallace JL, McKnight W, Wilson TL, Del Soldato P, Cirino G. Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. Am J Physiol 1997;273:G1246-51.
108. Wallace JL, Muscara MN, McKnight W, Dicay M, Del Soldato P, Cirino G. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. Thromb Res 1999;93:43-50.
109. Bolanos JP, Almeida A. Roles of nitric oxide in brain hypoxiaischemia. Biochim Biophys Acta 1999;1411:415-36.
110. Coert BA, Anderson RE, Meyer FB. A comparative study of the effects of two nitric oxide synthase inhibitors and two nitric oxide donors on temporary focal cerebral ischemia in the Wistar rat. J Neurosurg 1999;90:332-8.
111. Babu BR, Griffith OW. Design of isoform-selective inhibitors of nitric oxide synthase. Curr Opin Chem Biol 1998;2:491-500.
112. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339:533-41.
113. Chin-Dusting JP, Kaye DM. Restoration of nitric oxide function in human hyperlipidaemia, congestive heart failure and liver cirrhosis. Clin Exp Pharmacol Physiol 1998;25:645-52.
114. Meyer KC, Love RB, Zimmerman JJ. The therapeutic potential of nitric oxide in lung transplantation. Chest 1998;113:1360-71.